in vivo News and Research

RSS

Collegium commences enrollment in Oxycodone DETERx Phase 3 study in chronic lower back pain

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain today announced that it has initiated enrollment in its Phase 3 clinical study for Oxycodone DETERx (COL-003).

30 Aug 2012

SPR microscopy examines binding kinetics of membrane proteins

Proteins adorning the surfaces of human cells perform an array of essential functions, including cell signaling, communication and the transport of vital substances into and out of cells. They are critical targets for drug delivery and many proteins are now being identified as disease biomarkers - early warning beacons announcing the pre-symptomatic presence of cancers and other diseases.

29 Aug 2012

Proteonomix enters license agreement for new anti-tumor technology

Proteonomix, Inc., a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced that it has entered into an exclusive worldwide license agreement for a novel source of primary human cells that secrete a factor capable of inhibiting tumor cell growth and causing tumor cell death.

23 Aug 2012

Newly discovered on/off switch in enzymes may help battle fat-related disease

Enzymes involved in breaking down fat can now be manipulated to work three times harder by turning on a molecular switch recently observed by chemists at the University of Copenhagen. Being able to control this chemical on/off button could have massive implications for curing diseases related to obesity including diabetes, cardio vascular disease, stroke and even skin problems like acne. But the implications may be wider.

23 Aug 2012

Alcohol can cause more than one pattern of birth defects

A collaborative research effort by scientists at the University of North Carolina School of Medicine, Duke University, and University College of London in the UK, sheds new light on alcohol-related birth defects.

23 Aug 2012

Anti-cancer regimens with multiple modes of action increase treatment effectiveness

Cancer may be the Harry Houdini of diseases—it often finds devious ways to escape treatment. Because cancer disables our cellular quality control mechanisms, rampant mutations that cause tumor cells to grow uncontrollably can also generate resistance to anticancer drugs. Even if 99 percent of the tumor is destroyed, that 1 percent can come roaring back. How do we knock out that 1 percent? By attacking the cancer from multiple angles, using multiple treatments and strategies.

20 Aug 2012

Scientists demonstrate automated worm sorter for biological research

Research into the genetic factors behind certain disease mechanisms, illness progression and response to new drugs is frequently carried out using tiny multi-cellular animals such as nematodes, fruit flies or zebra fish.

20 Aug 2012

Non-antibiotic compounds can prevent urinary tract infections

The latest episode in the American Chemical Society's (ACS') award-winning Global Challenges/Chemistry Solutions podcast series describes a potential new approach for treating urinary tract infections (UTIs) - which affect millions of people annually - without traditional antibiotics. Because it involves non-antibiotic compounds, the approach would not contribute to the growing problem of antibiotic-resistant bacteria, or "superbugs."

16 Aug 2012

New type of medical imaging could help doctors spot tumors more quickly

Scientists from the University of Southern California in Los Angeles and Washington University in St. Louis have developed a new type of medical imaging that gives doctors a new look at live internal organs.

14 Aug 2012

Theranostic imaging targets and tracks potent drug therapies to prostate cancer cells

Experimenting with human prostate cancer cells and mice, cancer imaging experts at Johns Hopkins say they have developed a method for finding and killing malignant cells while sparing healthy ones.

9 Aug 2012

Prostate cancer cells can be killed by theranostic imaging without harming healthy cells

Experimenting with human prostate cancer cells and mice, cancer imaging experts at Johns Hopkins say they have developed a method for finding and killing malignant cells while sparing healthy ones.

8 Aug 2012

BioDiem granted European patent for antimicrobial drug

Australian vaccine development company BioDiem Ltd (ASX: BDM) announced today the successful granting of a key European patent for its synthetic antimicrobial compound BDM-I. BDM-I is a novel compound active against a range of pathogenic micro-organisms including bacteria, fungi and protozoa. The patent provides protection around BDM-I as a treatment for vulvovaginitis, a general term for inflammation of the vulva or vagina.

7 Aug 2012

Vorinostat drives HIV from hiding

The addition of vorinostat to current antiretroviral therapy regimens can potentially help to eradicate hidden pockets of dormant human immunodeficiency virus, according to study results published in Nature.

6 Aug 2012

Aquapharm discovers new antibiotic compound against multi-drug resistant bacteria

A significant discovery in the development of next-generation antibiotics has been made by Scottish biotechnology company Aquapharm.

6 Aug 2012

Biomimetic bioartificial livers and cell toxicity assays: an interview with Dr. Joris Braspenning, CEO Medicyte

Biomimetic bioartificial livers are liver organoids based on synthetic equivalents of the human extracellular matrix (ECM) which will be seeded with human cells.

1 Aug 2012

Hydroxychloroquine fails to modify HIV in patients not taking ART

The use of hydroxychloroquine does not reduce CD8 cell activation in HIV-infected patients not taking antiretroviral therapy, research shows.

30 Jul 2012

Study extends scientific understanding of how pheromones activate the vomeronasal organ

The vomeronasal organ (VNO) is one of evolution's most direct enforcers. From its niche within the nose in most land-based vertebrates, it detects pheromones and triggers corresponding basic-instinct behaviors, from compulsive mating to male-on-male death matches. A new study from the Stowers Institute for Medical Research, published online in Nature Neuroscience on July 29, 2012, extends the scientific understanding of how pheromones activate the VNO, and has implications for sensory transduction experiments in other fields.

30 Jul 2012

Neurotez receives U.S. patent for Leptin to treat Alzheimer's

Neurotez, Inc. today announced the grant of U.S. Patent number 8,227,408 by the United States Patent and Trademark Office covering the company's lead product candidate, Leptin. The patent protects use of the hormone Leptin for treating a progressive cognitive disease, disorder or condition, such as Alzheimer's disease (AD), resulting from accumulation of an amyloid peptide or for improving resilience of cognitive function by modulating the accumulation of the amyloid peptide in brain.

30 Jul 2012

OX40 molecule responsible for airway inflammation in the lungs

A research team led by Xian Chang Li, MD, PhD, Brigham and Women's Hospital (BWH) Transplantation Research Center, has shed light on how a population of lymphocytes, called CD4+ T cells, mature into various subsets of adult T helper cells.

30 Jul 2012

Novel method of identifying molecules that can help prevent diabetes

Pancreatic beta cells produce insulin, responsible for controlling blood sugar levels and thus essential for our survival. Among the numerous factors that affect the workings of these cells, a protein called Cx36 was identified a few months ago by a research team at the UNIGE.

27 Jul 2012